Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples